Phellinus Linteus (Meshima).

Both mushrooms carry branched beta-glucans that engage dectin-1 and complement receptor 3 on innate immune cells. The backbones differ in branching, so a blend presents the same receptor family with a wider range of polysaccharide shapes.

Maitake beta-glucans bind the same dectin-1 receptor on macrophages and dendritic cells. Pairing two fruiting-body sources raises total glucan delivered per serving without leaning on one supply.

Shiitake supplies lentinan-type 1,3-beta-glucan, a well characterised ligand for the same innate receptors. The two species give different degrees of branching on one shared signalling route.

Yeast 1,3/1,6-beta-glucan is the reference ligand for dectin-1, the same receptor mushroom glucans engage. Combining a yeast and a fungal source raises the standardised glucan content of a blend that is otherwise hard to quantify.

Vitamin D signalling through the VDR shapes how monocytes and macrophages respond once a pattern receptor such as dectin-1 is engaged. The pairing supplies the ligand and the nuclear-receptor context it acts within.

Astragalus polysaccharides act on toll-like receptor 4 rather than dectin-1, so the two engage separate arms of innate pattern recognition rather than the same receptor twice.

Neutrophils and lymphocytes concentrate ascorbate and depend on it for normal oxidative burst and chemotaxis. It supports the cells that mushroom glucans signal to.

Both fungi build their cell walls from beta-1,3-glucan with beta-1,6 branch points, the structural motif recognised by dectin-1 and complement receptor 3 on innate immune cells. Combining two such extracts raises the total glucan load and widens the range of branch patterns and attached proteoglycan presented. Receptor engagement is the mechanism; a joint clinical effect is not established.

Cordyceps contributes its own beta-glucans plus nucleoside constituents such as adenosine and cordycepin, so the pair is not simply more of the same molecule. Stacking mushroom extracts is standard formulation practice for that reason. What each contributes depends on the extraction route, since nucleosides and glucans partition differently.

Hericium contributes beta-glucan on the polysaccharide side and hericenone and erinacine terpenoids on the alcohol-soluble side. Phellinus contributes glucan plus hispidin-type polyphenols. A dual extraction of either captures both fractions, which is why the two are often paired in the same blend.

Isolated 1,3/1,6 beta-glucan and a Phellinus hot-water extract engage the same innate receptors, so a formulator adding both is raising the dose of one recognised structure rather than adding a second mechanism. Molecular weight and branching frequency, not the source name, drive how strongly a glucan is recognised. That makes the pairing a dose decision.

Oat beta-glucan is a mixed (1,3)(1,4) linear chain that works by viscosity in the gut lumen, while fungal beta-glucan is (1,3) with (1,6) branches and is an innate immune receptor ligand. They are not interchangeable and stacking them adds two unrelated functions, not a bigger version of one. This row exists mainly to stop the two being read as the same ingredient.

Selenium is required for glutathione peroxidase and thioredoxin reductase, the enzymes that handle peroxides generated during an innate immune response. Phellinus extracts carry hispidin-class polyphenols that act as direct reductants. Enzymatic and non-enzymatic antioxidant capacity are different layers, which is why they combine sensibly.

Zinc is needed for normal development and signalling of the same innate and adaptive cell populations that respond to fungal glucans, and inadequate zinc status limits that response. Supplying the receptor ligand and the nutrient the responding cells require are separate contributions. Neither claim depends on a combination trial.

Phellinus carries hispidin and phelligridin polyphenols with catechol-type reducing groups, and quercetin is chemically similar in that respect. Pairing them raises total polyphenol reducing capacity, which registers as antioxidant status markers rather than as an outcome. Both are also poorly absorbed intact, so exposure depends heavily on the formulation.

Most of a high molecular weight fungal glucan is not absorbed; it reaches the colon, where saccharolytic bacteria partially ferment it to short-chain fatty acids. That makes the resident microbiota part of how a mushroom extract acts, and adding a fermenting organism changes what is produced. The combination is mechanistically grounded and clinically untested here.

Lactoferrin acts on mucosal surfaces by binding iron and interacting with microbial membranes, an entirely different route from glucan receptor engagement. The two are commonly formulated together in immune-support products. No combination trial is cited.

Propolis carries caffeic acid esters and flavonoids, adding polyphenol reducing capacity beside the fungal glucan and hispidin fraction. The pairing is long-standing in traditional immune-support preparations. Confidence here reflects convention plus chemistry rather than trial evidence.

Silymarin flavonolignans act on hepatocyte membranes and phase II enzyme expression, while Phellinus polysaccharides act at the gut and immune-cell interface. Blends put them together to cover unrelated tissues rather than to potentiate one another. No combination evidence is cited and neither claim here is a disease claim.